Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial

Abstract

In patients with recurrent nasal polyposis receiving topical corticosteroids who required surgery, mepolizumab treatment led to a greater reduction in the need for surgery and a greater improvement in symptoms than placebo.

Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review

“…However, the subgroup analysis in this study showed that no difference for baseline TPSs and local IL-5 levels was found. Similarly, in the Bachert et al (23) study, mepolizumab caused a significant improvement in the treatment group as compared to control group from week 9 to week 25.…”

“…On the contrary, the mean difference between mepolizumab and control group in PNIF values was statisticallly significant (p=0,027, in the second mepolizumab study (23) . At last, Bachert et al (22) reported a statistically significant mean difference in PNIF for dupilumab group vs placebo (p=0,002).…”

“…Finally, SNOT-22 was improved significantly by the use of both dupilumab (22) and mepolizumab (23) (p<0,001 and p=0,005, respectively) (23) .…”

“…Six studies fulfilled the inclusion criteria (18)(19)(20)(21)(22)(23) . Αll studies were RCTs and were published between 2006 and 2017.…”

“…Three of the studies were single-site (19)(20)(21) while the other three were multisite (18,22,23) . Subjects were randomized to receive: anti-IL5 therapy with reslizumab (18) or mepolizumab (20,23) in three studies, anti-IgE therapy with omalizumab in two studies (19,21) and anti-IL-4Rα therapy with dupilumab in the last RCT (22) . The characteristics of the six included studies as well as baseline demographic and clinical characteristics of the patients are presented in Table 2 and 3.…”